Releases
MGTX
6.16
-0.89%
-0.06
  • All
  • Financials
  • Insiders
More
Webull provides the latest Meiragtx Holdings Plc (MGTX) stock and general news. This information may help you make smarter investment decisions.
About MGTX
MeiraGTx Holdings PLC is an integrated, clinical stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. It has six programs in clinical development and a pipeline of preclinical and research programs. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-Linked Retinitis Pigmentosa Associated with Mutations in the RPGR Gene; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the Treatment of LCA4. It also provides AAV-hAQP1 for the Treatment of Radiation-Induced Grade 2/3 Xerostomia, AAV-RDH12 for the Treatment of RDH12 Mutation-Associated Retinal Dystrophy, AAV-RDH12 for the Treatment of RDH12 Mutation-Associated Retinal Dystrophy and others.